Loss of LKB1 is associated with increased metastasis and poor prognosis in lung cancer, but the development of targeted agents is in its infancy. Here we report that a glutaminolytic enzyme glutamate dehydrogenase 1 (GDH1), upregulated upon detachment via pleomorphic adenoma gene 1 (PLAG1), provides anti-anoikis and pro-metastatic signals in LKB1-deficient lung cancer. Mechanistically, the GDH1 product α-KG activates CamKK2 by enhancing its substrate AMPK binding, which contributes to energy production that confers anoikis resistance. The effect of GDH1 on AMPK is evident in LKB1-deficient lung cancer, where AMPK activation predominantly depends on CamKK2. Targeting GDH1 with R162 attenuated tumor metastasis in patient-derived xenograft model and correlation studies in lung cancer patients further validated the clinical relevance of our finding. Our study provides insight into the molecular mechanism by
INTRODUCTION
Tumor metastasis is a major contributor to deaths from nearly all types of cancers (Steeg, 2016) . The metastatic cascade represents a multi-step biological process (Fidler, 2003; Gupta and Massague, 2006) . Anoikis, which is a form of programmed cell death resulting from loss of cell and extracellular membrane interaction, is known as a physiological barrier to metastasis (Fidler, 2003; Paoli et al., 2013) . Cancer cells must develop anoikis resistance in order to survive in the circulation before forming metastatic foci in distant organs (Kim et al., 2012; Simpson et al., 2008) .
Lung cancer is the leading cause of cancer death worldwide and frequently metastasizes to distant organs. The five-year survival rate for metastatic lung cancer is only around 3% (Dela Cruz et al., 2011) . 85% of lung cancer cases are non-small cell lung carcinoma (NSCLC) . The development of targeted agents specifically in metastatic lung cancer is still very much in its early phase. Thus, it is critical to identify and validate promising therapeutic targets to enable significant clinical gains. About one third of lung cancer patient tumors lack or harbor inactive tumor suppressor liver kinase B1 (LKB1), and LKB1 deficiency is associated with increased metastatic rates and decreased survival in patients (Sanchez-Cespedes et al., 2002) . LKB1 directly phosphorylates 5′ AMP-activated protein kinase α (AMPKα) at T172 and activates AMPK. AMPKα is also phosphorylated by other upstream kinases, calcium/calmodulin dependent protein kinase kinase 2 (CamKK2) and TGF-β-activated kinase 1 (TAK1) (Hardie et al., 2012; Luo et al., 2010) . AMPK is a central regulator of cellular metabolism and energy homeostasis, which is composed of α-catalytic and two regulatory subunits β and γ (Hawley et al., 2003) . AMPK contributes to prosurvival signaling by inhibiting the mTOR pathway (Avivar-Valderas et al., 2013; Kim et al., 2011; Ng et al., 2012) . AMPK can exert pro-or anti-tumorigenic roles in cancer depending on context (Faubert et al., 2015; Liang and Mills, 2013) . AMPK-mediated cell survival may be critical when cancer cells are under conditions that are unfavorable for cell proliferation such as detachment from the matrix for circulation in the bloodstream during metastasis, through mechanisms that are not yet fully explored.
To generate energy and biomass for tumor growth, cancer cells are well documented to have enhanced metabolic requirements, including elevated aerobic glycolysis and glutaminolysis (Hsu and Sabatini, 2008; Kim and Dang, 2006; Warburg, 1956) . We reported that activation of metabolic enzymes including pyruvate dehydrogenase kinase and 6-phosphogluconate dehydrogenase contributes to altered cancer cell metabolism and tumor growth (Hitosugi et al., 2011; Lin et al., 2015) . In addition, we found that a glutaminolytic enzyme, glutamate dehydrogenase 1 (GDH1), promotes tumor growth by regulating redox homeostasis through its product α-KG and subsequent metabolite fumarate by activating an ROS scavenging enzyme glutathione peroxidase 1 (GP×1) Jin et al., 2015) . However, how this altered metabolism contributes to tumor metastasis and anoikis resistance remains largely unknown. While elevated aerobic glycolysis is a hallmark of proliferative cancer cells, emerging evidence suggests that disseminated metastatic tumor cells have a different metabolic phenotype compared to proliferating tumor cells (Weber, 2016) . For instance, studies reveal that cancer cells switch from oxidative to reductive metabolism in utilizing glutamine during matrix detachment and support redox homeostasis via isocitrate dehydrogenase 1 (IDH1) (Jiang et al., 2016) . Extracellular matrix (ECM) detached cells are known to be nutrient-starved which limits energy production, whereas estrogen-related receptor or oncogenes such as ErbB2 maintain TCA flux through PDK4 upregulation (Grassian et al., 2011; Kamarajugadda et al., 2012) . In addition, studies show that genes associated with mitochondrial biogenesis and oxidative phosphorylation, rather than those involved in the Warburg effect, are upregulated in circulating tumor cells compared with primary tumor cells (LeBleu et al., 2014) . Understanding the mechanisms underlying the metabolic changes associated with cancer spread and identifying metabolic targets that promote tumor metastasis may lead to improved clinical outcomes for patients with metastatic cancers.
Here, we uncover the molecular mechanism by which an altered tumor metabolism provides metabolic advantages to cancer cells during dissemination and contributes to tumor metastasis in lung cancer. In particular, we report that glutaminolysis, a mitochondrial pathway that consumes an alternative metabolic substrate glutamine, contributes to antianoikis and pro-metastatic signaling through GDH1 and its product α-KG by activating the CamKK2-mediated AMPK signaling pathway.
RESULTS

GDH1 is upregulated in detached metastatic human lung cancer cells
To better understand the link between glutaminolysis and tumor metastasis, we first screened for a factor in the glutaminolysis pathway that contributes to the acquisition of anoikis resistance, the prerequisite for metastasis. We induced anoikis by culturing cells under detached conditions and monitored any expression changes in glutaminolytic enzymes.
Among 11 enzymes tested, GDH was commonly upregulated in a panel of lung cancer cells (Figures 1A and 1B) . Although the GDH primers do not distinguish the two isoforms GDH1 and GDH2, we found that GDH1 is the predominant isoform in lung cancer cells through a diagnostic restriction digest ( Figure S1 ) (Shashidharan et al., 1994) . We next examined the effect of blocking glutamine metabolism on anoikis resistance in a panel of lung cancer cells. Targeting glutaminolysis by glutamine deprivation or glutamine antagonist 6-diazo-5oxo-L-norleucine (DON) treatment for a short period of time (24 hours) induced significantly more apoptotic cell death when cells were detached than attached in majority of lung cancer cells tested ( Figure 1C) . Interestingly, the cells that responded to glutaminolysis inhibition in terms of anoikis induction were commonly lacking LKB1. These data suggest that although GDH1 expression is induced upon detachment in all cells regardless of LKB1, glutaminolysis may be critical in protecting cells from anoikis only in lung cancer cells that are lack of LKB1.
Reliance of GDH1 on anoikis resistance depends on LKB1 status
To investigate the effect of LKB1 status on GDH1-mediated anoikis resistance, we generated isogenic pairs of lung cancer cell lines with different LKB1 status. Expression of wild-type (WT) but not a kinase-dead (KD) form of LKB1 in LKB1-deficient cells abolished the effect of GDH1 knockdown on anoikis induction ( Figure 1D upper) . On the contrary, knockout of LKB1 in LKB1 wt cells restored the GDH1 knockdown effect, resulting in enhanced anoikis induction ( Figure 1E upper) . Interestingly, LKB1 removal led to decreased phosphorylation of its downstream effectors AMPK and ACC1, and GDH1 knockdown led to further attenuation of these phosphorylations specifically in cells lacking LKB1 ( Figure 1D and 1E lower). This observation suggests that GDH1 contributes to anoikis resistance and activation of LKB1 downstream effector AMPK exclusively in the absence of LKB1.
GDH1 confers anoikis resistance and metastatic potential to lung cancer cells
To further demonstrate whether GDH1 is important for anti-anoikis signaling in lung cancer, we assessed the impact of targeting GDH1 on anoikis induction of a panel of NSCLC cells using multiple shRNA clones. GDH1 knockdown sensitized a group of lung cancer cells including A549, H157, and H460 to detachment-induced apoptosis which are LKB1 null, whereas a group of cells that harbor wild-type LKB1, H1299, H292, and H358, did not respond to GDH1 knockdown in terms of anoikis induction (Figure 2A and S2A). And the GDH1 contribution was specific to detachment-induced apoptosis ( Figure S2B ). Detachment-induced apoptosis in GDH1 knockdown cells was accompanied by a reduction in mitochondrial membrane potential and cytochrome c release ( Figures S2C and S2D ). Cell permeable α-KG, product of GDH1, restored the enhanced anoikis induction and cytochrome c release in LKB1-deficient GDH1 knockdown cells ( Figures 2B, S2E , and S2F). α-KG but not other TCA intermediate metabolites, including succinate, malate, or fumarate, rescued the anoikis induced by GDH1 targeted downregulation ( Figure 2C ). Cell permeable dimethyl metabolites were treated with concentrations that fully restore corresponding metabolite levels in detached GDH1 knockdown cells ( Figure S2G ). Moreover, recovery of GDH activity by overexpressing wild type GDH1 but not enzymedead mutant GDH1 R443S rescued the anoikis resistant potential in GDH1 knockdown cells ( Figure 2D ) (Zaganas et al., 2002) . Furthermore, restoration of decreased α-KG level by overexpressing other α-KG producing mitochondrial enzymes such as glutamic-oxaloacetic transaminase 2 (GOT2) again fully rescued anoikis resistance in GDH1 knockdown cells ( Figure 2E ). These data together suggest that enzymatic activity of GDH1, in particular its product α-KG, contributes to anoikis resistance. We next functionally validated the role of GDH1 in tumor metastasis using a xenograft model of experimental metastasis, in which tumor cells are injected directly into the systemic circulation. Anoikis resistance can be precisely monitored using this model since the number and type of cells introduced into the circulation can be controlled. The mice transplanted with GDH1 knockdown A549 or H460 cells showed reduced metastasis when compared with the control group injected with cells harboring empty vector, suggesting that GDH1 promotes metastatic potential in vivo (Figures 2F and 2G) .
GDH1 contributes to anoikis resistance by regulating energy balance through the CamKK2-AMPK pathway
To identify the metabolic advantages GDH1 provides to confer anoikis resistance, we performed a series of metabolic assays in lung cancer cells with GDH1 knockdown. Loss of matrix attachment resulted in metabolic impairment limiting the uptake of nutrients and consequently decreasing flux through metabolic pathways including the TCA cycle, and glutamine metabolism was further decreased with the application of GDH1 knockdown ( Figure S3A -S3D). Consistent with previous reports, detachment was accompanied by enhanced reductive carboxylation of glutamine, assessed by increased labelling at citrate m +5, whereas glutamine oxidation reflected by the m+4 fraction of citrate was decreased upon detachment ( Figure S3E ). However, both reductive and oxidative glutamine metabolism were reduced upon loss of GDH1, indicating that GDH1 plays a critical role in glutamine metabolism in all cases. GDH1 knockdown did not influence anabolic biosynthesis under anoikis-induced conditions ( Figure S3F ). In contrast to normal culture conditions where GDH1 knockdown impaired ROS regulation through GPx1, GDH1 knockdown did not alter intracellular ROS levels under detached culture conditions ( Figure S3G ), and the antioxidants N-acetyl-L-cysteine (NAC) and tiron could not rescue the anoikis resistance lost due to GDH1 knockdown ( Figure S3H ). Moreover, knockdown of GPx1, the ROS scavenging enzyme controlled by GDH1, did not sensitize cells to anoikis induction ( Figure  S3I ). GDH1 may not predominantly contribute to redox homeostasis in detached cells where altered metabolism such as reductive carboxylation controls ROS through a different mechanism such as IDH1. These data suggest that GDH1 provides metabolic advantages other than redox regulation or anabolic biosynthesis to confer anoikis resistance. Indeed, GDH1 knockdown decreased ATP levels and oxygen consumption rates whereas α-KG restored the effect under detached culture conditions only in LKB1-defiicent cells, suggesting that GDH1 contributes to energy metabolism in LKB1-deficient cancer cells once detached from the extracellular matrix (Figures 3A, S3J-S3L).
To explore the mechanism by which GDH1 contributes to anti-anoikis signaling, we examined whether GDH1 knockdown attenuates the activity of AMPK, a master regulator of cellular energy homeostasis. We found that AMPK activity, assessed by AMPKα T172 phosphorylation, was significantly attenuated in GDH1 knockdown cells compared to control cells, whereas the GDH1 product α-KG but not other intermediate metabolites rescued the decreased AMPK activation in GDH1 knockdown cells when detached (Figures 3B left and S4A) . In agreement, rescue of intracellular α-KG either by GDH1 WT or another α-KG producing enzyme, GOT2, reactivated AMPK in GDH1 knockdown cells (Figures 3B right and 3C) . These results further demonstrate that the GDH1 product α-KG plays a pivotal role in AMPK activation and anoikis resistance. GDH1 knockdown decreased intracellular ATP level and anoikis resistance ( Figure 3D and 3E; left two panels). Decreased ATP was not rescued by the addition of caspase inhibitor Z-VAD suggesting that the change in ATP production was not a consequence of anoikis, but that impaired energy homeostasis upon GDH1 knockdown leads to anoikis activation ( Figure S4B ). Restoration of active AMPK by AMPKα overexpression or AMPK activator A769662 significantly rescued the GDH1 knockdown effect on anoikis (Figures 3D and 3E; right two panels). Moreover, targeted downregulation of AMPK mimicked the GDH1 knockdown effect in terms of anoikis induction ( Figure 3F ). In addition, enhanced anoikis and decreased ATP levels in GDH1 knockdown cells were rescued by treatment with the mTOR inhibitor rapamycin ( Figure 3G ). These data together suggest that GDH1 and its product α-KG potentiate anoikis resistance by triggering energy metabolism through AMPK activation and consequent suppression of mTOR signaling. However, the effect of α-KG on AMPK was indirect, since the activity of AMPK by phosphorylation and dephosphorylation was not altered by various concentrations of α-KG including the physiological range in vitro (Figures 3H and S4C) .
To investigate how GDH1 contributes to AMPK activation and anoikis resistance in an LKB1 independent manner, we tested the effect of targeting GDH1 on the activities of CamKK2, the known alternative upstream kinases of AMPK. GDH1 knockdown decreased the activity of CamKK2, which was fully rescued by treatment with α-KG ( Figure 4A ). CamKK2 transient knockout approach revealed that CamKK2 largely governs AMPK activity and anoikis resistance in LKB1-deficient cells, but not in LKB1 wt cells ( Figure  4B ). To further validate that GDH1 controls anoikis resistance through CamKK2, we tested whether CamKK2 overexpression can reverse the GDH1 knockdown effect. Indeed, overexpression of CamKK2 rescued the decreased AMPK activity and anoikis resistance in GDH1 knockdown cells ( Figure 4C ). In contrast, treatment of CamKK2 inhibitor STO-609 attenuated AMPK activation and sensitized the cells to anoikis induction, while GDH1 knockdown cells were resistant to the CamKK2 inhibitor ( Figure 4D ). Moreover, CamKK2 inhibition using BAPTA eradicated the α-KG rescue effect in GDH1 knockdown cells ( Figure S5A ). These data together suggest that GDH1 and its product α-KG promote antianoikis signaling by activating AMPK through CamKK2, and this contribution is pronounced in LKB1-deficient cells where CamKK2 plays a dominant role in activating AMPK.
We next explored the molecular mechanism underlying α-KG mediated activation of CamKK2. Radiometric metabolite-protein interaction assay and cellular thermal shift assay revealed that α-KG specifically binds to CamKK2 ( Figures 4E and 4F ). Calcium controls the activity of CamKK2. Manipulation of GDH1 and its product α-KG did not alter calcium levels suggesting that GDH1 and α-KG mediated CamKK2 activation does not occur through calcium ( Figure S5B ). Whereas, treatment with cell permeable α-KG enhanced CamKK2 substrate AMPKα binding to CamKK2 in cells ( Figure 4G ). Furthermore, α-KG treatment increased AMPKα binding to CamKK2 in a dose-dependent manner in vitro using purified AMPKα-CamKK2-calmodulin complex ( Figure 4H ). These data suggest that α-KG promotes CamKK2 activity by enhancing CamKK2 binding to its substrate AMPKα.
GDH1 small molecule inhibitor R162 attenuates anoikis resistance and tumor metastasis
Our finding that GDH1 is upregulated in metastatic lung cancer and GDH1 knockdown attenuates anoikis resistance and tumor metastasis implicates GDH1 as an attractive antimetastasis target. We previously screened and identified purpurin and its cell permeable analog R162 as GDH1 selective inhibitors (Jin et al., 2015) . Treatment with R162 significantly sensitized LKB1-deficient A549, H157, and H460 cells to anoikis induction, and this was fully rescued by α-KG treatment ( Figures 5A and S6 ). The dose of 20 mg/kg/day R162 treatment significantly attenuated metastatic potential in a xenograft mouse model injected with luciferase labeled A549 cell lines ( Figure 5B ). To test the efficacy of GDH1 inhibitor as an anti-metastasis drug in a more clinically relevant setting, we established a patient-derived xenograft (PDX) model using an LKB1-deficient lung cancer patient-derived tumor ( Figure 5C ). The PDX tumors injected in an experimental metastasis model through the tail vein survived in the circulation and colonized to liver, lungs and other organs, whereas R162 treatment dramatically attenuated their metastatic potential in PDX mice ( Figures 5D-5F ). These results together suggest that GDH1 is a promising antimetastasis target and that the GDH1 inhibitor R162 is a potent agent for anti-metastasis therapy in LKB1-deficient human lung cancer.
Transcription factor PLAG1 controls GDH1 expression in lung cancer
To glean comprehensive mechanistic insight into how GDH1 is upregulated in anoikis induced lung cancer cells, we performed transcription factor (TF) activation profiling using attached and detached A549 cells. The TF Activation Profiling Array monitors activities of 96 cellular TFs, including NFκB, HIF1, and p53, that are known to play essential roles in regulating gene expression (Toubal et al., 2013) . Five among 96 TFs were activated more than 1.8-fold when cells were cultured under detached conditions, including PLAG1, SATB1, and Snail3 ( Figure 6A ). To further examine whether any of these TFs activate the GDH1 promoter, we overexpressed the top 3 potential candidates PLAG1, SATB1, and Snail3, and performed a GDH1 promoter reporter activity assay. PLAG1 but not SATB1 or Snail3 enhanced GDH1 promoter activity ( Figure 6B ). A promoter reporter activity assay using GDH1 and GDH2 promoter reporters revealed that PLAG1 mainly enhances GDH1 promoter activity ( Figure 6C ). In addition, chromatin immunoprecipitation (ChIP) assay showed that the GDH1 promoter interacts with PLAG1 but not SATB1 in 293T cells and lung cancer A549 cells ( Figure 6D ). Moreover, knockdown of PLAG1 attenuated GDH1 expression and GDH1 promoter activity, and enhanced apoptosis under detached conditions, suggesting that PLAG1 contributes to GDH1 expression and confers anoikis resistance in lung cancer cells ( Figure 6E ).
Finally, we clinically validated our functional studies of tumor metastasis using a panel of primary and metastatic paired lung cancer patient tumor tissues. LKB1 status of the 80 paired tumors was determined by LKB1 immunohistochemistry (IHC) staining ( Figure 7A ). PLAG1 expression significantly correlated with the status of metastasis in both LKB1 negative and positive tumors ( Figure 7B ). While GDH1 expression levels were higher in metastasized tumors than the paired primary tumors when lacking LKB1, there was no significant difference in the tumor pairs expressing LKB1 ( Figure 7C ). In line with the correlation between metastatic status and PLAG1 or GDH1 expression, the staining intensity of PLAG1 and GDH1 positively correlated in both LKB1-negative and -positive sets of tumors ( Figure 7D) . In contrast, a significant positive correlation between GDH1 expression and AMPKα phosphorylation only existed in LKB1-deficient tumors, but not in tumors carrying LKB1 ( Figure 7E ). Our finding was further clinically validated by analyzing TCGA lung cancer datasets. A positive correlation between GDH1 expression and AMPK activation only exists in lung cancer patients whose tumors lack functional LKB1, but not in patients with tumor carrying wild type LKB1, further supporting that GDH1 contributes to AMPK activation in tumor cells lacking LKB1 ( Figure 7F ). Our study supports the role of GDH1 signaling as a metastasis-promoting pathway in lung cancer lacking LKB1. Although PLAG1 induces GDH1 regardless of LKB1 status, only LKB1-deficient tumors may benefit from GDH1 expression and acquire metastatic potential by GDH1-mediated activation of CamKK2 and its downstream effector AMPK.
DISCUSSION
The acquisition of anoikis resistance allows tumor cells to survive while they circulate in the bloodstream and is vital to metastatic progression, but the molecular mechanism by which tumor cells develop anoikis resistance remains unclear. Our findings delineate this mechanism by revealing a crosstalk between mitochondrial glutamine metabolism and tumor metastasis. We demonstrate that enhanced expression of GDH1 mediated by a transcription factor PLAG1 following detachment activates CamKK2 and its downstream substrate AMPK, which provides anti-anoikis and pro-metastatic signaling to lung cancer cells. Although GDH1 is commonly induced by PLAG1 upon detachment, GDH1 is critical in LKB1-null cells where GDH1-mediated activation of CamKK2 plays a pivotal role in activating AMPK that contributes to anoikis resistance and tumor metastasis, while GDH1 has less effect in cells with LKB1-wt where AMPK activation is predominantly dependent on LKB1 not the GDH1 signaling effector, CamKK2 ( Figure 7G ). Therefore, targeting GDH1 would be a promising therapeutic opportunity to prevent the development of metastasis in LKB1-deficient lung cancer.
Our study suggests a differential role of GDH1 in the metabolism of lung cancer cells with different LKB1 status. Our results also reveal that the status of LKB1 differentially reprograms the metabolic requirements in cancer cells for survival during tumor metastasis. We recently reported that GDH1 is important for redox homeostasis by controlling its product α-KG and a subsequent metabolite fumarate, which provides a proliferative advantage for rapidly growing tumors. While GDH1 is commonly important for redox regulation, cancer cell proliferation and tumor growth despite LKB1 status, GDH1 has an additional role in the regulation of bioenergetics in LKB1-null cells upon detachment. Tumor cells may slow down the generation of building blocks or the management of redox balance as a means for bioenergetics conservation during extracellular membrane detachment, and elevated GDH1 may contribute to this response by having an additional role when tumor cells disseminate. However, there are reports implicating the role of redox regulation in anoikis resistance. Studies demonstrate that ROS is deleterious and must be neutralized by antioxidant enzymes in detached breast cancer cells (Avivar-Valderas et al., 2011; Davison et al., 2013; Schafer et al., 2009) . Conversely, hydrogen peroxide is reported as an anti-anoikis promoting factor by stabilizing the metastasis gene caveolin-1 in lung cancer (Rungtabnapa et al., 2011) . This implies that the metabolic demand for detached tumor cells may differ depending on cancer type and disparate metabolic conditions such as antioxidant enzyme activities.
We found that mechanistically, the GDH1 product α-KG activates CamKK2 by enhancing the binding of its substrate AMPK to CamKK2. This provides additional evidence that metabolic intermediates function as signaling molecules to allow crosstalk between metabolic pathways and cell signaling pathways. Detailed future study is warranted to decipher by which mechanism α-KG structurally recruits the substrate AMPK to CamKK2. AMPK has recently been implicated in anoikis resistance and is activated either by LKB1 or CamKK2 under detachment-induced stress (Sundararaman et al., 2016) . Enhanced AMPK is known to contribute to sustaining pro-survival signals after detachment by activating an autophagic pathway through Ulk1 phosphorylation and inhibiting mTOR through suppressing energy-demanding protein synthesis (Avivar-Valderas et al., 2013; Kim et al., 2011; Ng et al., 2012) . In addition, AMPK contributes to anoikis resistance in breast cancer by phosphorylating PEA15 at serine 16 (Hindupur et al., 2014) . We showed that GDH1mediated activation of AMPK contributes to anoikis resistance through mTOR inhibition in LKB1-deficient lung cancer.
We identified PLAG1 as a transcription factor for GDH1. Although detachment commonly enhanced GDH1 expression, only LKB1-deficient cells benefit from enhanced GDH1 expression by α-KG-mediated CamKK2 activation. Moreover, our findings that GDH1 expression positively correlates with lung cancer metastatic progression and GDH1 knockdown not only reduces tumor growth, but also sensitizes cells to anoikis induction and attenuates tumor metastasis, suggest that GDH1 may represent an attractive anti-cancer and anti-metastasis target for the treatment of lung cancer depending on the LKB1 status. Compound R162, as a first generation of GDH1 small molecule inhibitor for GDH1-targeted lung cancer therapy, has shown promising efficacy in the treatment of lung cancer cells and in PDX mouse models of tumor metastasis. The strategy of targeting GDH1 has the potential to be commonly effective for all lung cancer patients with elevated glutamine metabolism, and more beneficial to those patients who are diagnosed with LKB1-deficient metastatic lung cancer, for which there is currently a lack of effective inhibitor. 
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were collected and the cell volume was estimated by comparing the size of the cell pellet with the size of known-volume PBS in a separate tube. Cell pellets were homogenized with assay buffer and the debris was removed by centrifugation. The supernatant was further deproteinized using Amicon Ultra-10k centrifugal filter (Millipore) and subjected to metabolites measurement according to the manufacturer's recommendation. Glucose consumption, lactate production and glutamine consumption were determined using commercial kits from Promega. Briefly, culture medium from cells cultured in attached or detached condition were collected at different timepoints and used for measurement of glucose, lactate and glutamine. Ammonia release in the cell culture medium was determined using Ammonia Assay Kit (Abcam). Oxygen consumption rate was measured using a clarktype oxygen sensor (Strathkelvin Instruments). For basal and maximum OCR, cells were sequentially treated with oligomycin (500 nM), FCCP (500 nM), and rotenone/antimycin A (1 μM) and analyzed using Seahorse XF24 analyzer (Agilent Technologies). For 14 C-RNA and 14 C-lipid syntheses, cells were spiked with 4 μCi/ml of D-[U-14 C] glucose or L-[U-14 C] glutamine (Perkin Elmer) for 2 hours. Extracted 14 C-RNA was quantified by liquid scintillation counting and normalized by the total amount of RNA. Lipids were extracted by 500 μL of hexane:isopropanol (3:2 v/v), air dried, suspended in 50 μL of chloroform, and subjected to scintillation counting. For glutaminolysis rate assay, glutamine oxidation measuring 14 CO 2 from 14 C glutamine was used to determine glutaminolysis rate. Briefly, cells were seeded under attached or detached condition in 6-cm dishes that were placed in a sealed 10-cm dish. After 24 h, cells were incubated with 4 μCi/ml of [U-14 C] glutamine for 4 h and the reaction was stopped by the addition of 200 μl of 70% perchloric acid. 0.5 ml of 3 M NaOH was injected to a cup placed next to the 6-cm dish to absorb all the released CO 2 from the cells. After 12 h incubation, 20 μl of NaOH was subjected to liquid scintillation counting. Cellular ROS was determined with carboxy-H 2 DCFDA (Invitrogen). Mitochondria membrane potential was determined using MitoProbe JC-1 Assay Kit (ThermoFisher). Intracellular calcium level was determined by ratiometric analysis of Fura Red (Invitrogen) and Fluo-3 (Invitrogen) staining using flow cytometry, according to manufacturer's instruction.
Metabolite extraction, GC-MS, and 13 C metabolic flux analysis-2×10 6 A549 cells without or with GDH1 shRNA were cultured under attached or detached conditions for 24 hours in glutamine-free RPMI-1640 medium containing 2 mmol/L [U-13 C 5 ] glutamine and 10% dialyzed FBS. Cells were rinsed with 0.9% saline solution and lysed with 500 μL ice-cold methanol for 1 min. 200 μL water containing 5μg/ml norvaline was added and vortexed. 500μL chloroform was added and vortexed again. After centrifugation at 13,000 rpm for 5 min, 500μL of the upper aqueous layer was collected and evaporated under vacuum at −4°C. Dried polar metabolites were processed for gas chromatography (GC) mass spectrometry (MS). Briefly, polar metabolites were derivatized using a Gerstel MultiPurpose Sampler. Methoxime-tBDMS derivatives were formed by addition of 15 μL 2% (w/v) methoxylamine hydrochloride (MP Biomedicals) in pyridine and incubated at 45°C for 60 min. Samples were silylated by addition of 15 μL of N-tert-butyldimethylsily-Nmethyltrifluoroacetamide (MTBSTFA) with 1% tert-butyldimethylchlorosilane (tBDMS) (Regis Technologies) and incubated at 45°C for 30 min. Derivatized samples were injected into a GC-MS using a DB-35MS column (Agilent J&W Scientific) installed in an Agilent 7890B GC system integrated with an Agilent 5977a MS. Samples were injected at a GC oven temperature of 100°C and held for 1 min before ramping to 255°C at 3.5°C/min then to 320°C at 15°C/min. Electron impact ionization was performed with the MS scanning over the range of 100-650 m/z for polar metabolites. Metabolite levels and mass isotopomer distributions of derivatized fragments were analyzed with an in house Matlab script, which integrated the metabolite fragment ions and corrected for natural isotope abundances.
In vitro kinase assays and phosphatase assay-For CamKK2 in vitro kinase assay, Radiometric metabolite-protein binding assay and cellular thermal shift assay -GST or flag tagged CamKK2 or AMPKα was purified from 293T cells. Bead-bound CamKK2 or AMPKα was incubated with 0.12 μCi of 14 C-α-KG or 14 C-fumarate for 30 min, washed, eluted, and radioactivity was detected by scintillation counting. Cellular thermal shift assay was performed as previously described (Gad et al., 2014; Martinez Molina et al., 2013) . In brief, 293T cells were transfected with flag-CamKK2 and treated with PBS, methyl-α-KG, or methyl-fumarate for 24 h. Cells were collected, aliquoted, and heated at 46, 49, 52, 55, 58, 61, 64, 67, and 70°C for 3 min. CamKK2 in the soluble fraction was quantified by FLAG immunoblot.
Transcription factor activity profiling-A549 cells were subjected to attached or detached conditions for 24 h, followed by nuclear protein extraction. The activities of 96 transcription factors were determined by TF Activation Profiling Plate Array (FA-1002, Signosis) according to the manufacturer's protocol.
Promoter reporter assay and ChIP assay-For GDH1 and GDH2 promoter report assay, PLAG1, SATB1, or Snail3 constructs were co-transfected with GDH promoter constructs, and dual luciferase reporter assay (Promega) was carried out according to the manufacturer's instruction. ChIP assay was performed using Millipore chromatin immunoprecipitation assay (Millipore). Briefly, flag-PLAG1 or V5-SATB1 was pulled down from transfected 293T cells. DNA was isolated from the immunoprecipitates and the GDH1 promoter region was amplified by PCR.
Xenograft studies-Nude mice or NOD SCID gamma (NSG) mice were intravenously injected with 2.5 × 10 6 of A549-luc-GFP or 2 × 10 6 of H460 cells, respectively. Bioluminescent imaging (BLI) vector were introduced into A549 cells for BLI (Kang et al., 2005; Ponomarev et al., 2004) . Metastasis was monitored by bioluminescence imaging (BLI) analysis as previously described . In brief, D-luciferin (75 mg/kg) was intraperitoneally administered and images were acquired using IVIS Imaging System (Perkin Elmer). For experimental lung patient-derived xenograft (PDX) metastasis model, fresh tumor (TKO-008) from LKB1-deficient small cell lung carcinoma PDX mice were digested with tissue dissociation buffer (0.1% collagenase, 0.01% hyaluronidase, 0.01% DNase I in HBSS) for 1 h at 37°C (Owonikoko et al., 2016; Petit et al., 2013) . The tumor cells were washed through a strainer with HBSS and counted. 2 × 10 6 live patient-derived tumor cells were injected into nude mice through the tail vein. For the R162 efficacy experiment, mice were intraperitoneally injected with vehicle control or R162 (20 mg/kg/ day), from the next day of xenograft injection.
Immunohistochemical staining-Paraffin-embedded lung cancer tissue microarrays (LC814 and LC817) containing primary and matched metastasized tumors from lymph nodes were obtained from US Biomax. IHC analyses were performed according to the previously described (Kang et al., 2010) . In brief, human tissue sections were deparaffinized, rehydrated, and incubated in 3% hydrogen peroxide to suppress endogenous peroxidase activity. Antigen retrieval was achieved by microwaving the sections in 10 mM Sodium Citrate (pH 6.0). Sections were incubation in 2.5% horse serum for blocking. The primary antibodies were applied to the slides at dilution of 1:250 (anti-LKB1 antibody), 1:200 (anti-PLAG1 antibody), 1:500 (anti-GDH1 antibody), and 1:100 (anti-p-AMPK T172 antibody) at 4°C overnight. Detection was achieved with the avidin-biotin complex system (Vector Laboratories). Slides were stained with 3,3′-diaminobenzidine, washed, counterstained with hematoxylin, dehydrated, treated with xylene, and mounted. Positive staining was identified using IHC signal intensity scored as 0, +1, +2, and +3.
Publicly available TCGA database analysis-GDH1 mRNA expression z-scores (RNA Seq V2 RSEM) and AMPKα T172p protein expression z-scores(RPPA) in TCGA Lung Adenocarcinoma (LUAD) Provisional were downloaded from cBioportal. LKB1 mutation status data from whole exome sequencing was acquired from Firehose. All data were downloaded on 09/01/2016 and Pearson correlation analysis was performed using Graphpad Prism 7. 
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